FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Front Vet Sci / Anti-inflammatory compounds reduce equine herpesvirus type 1...
Frontiers in veterinary science2023; 10; 1165917; doi: 10.3389/fvets.2023.1165917

Anti-inflammatory compounds reduce equine herpesvirus type 1 replication and cell-to-cell spread.

Abstract: Equine herpesvirus type 1 (EHV-1) is a highly transmissible pathogen that leads to a variety of clinical disease outcomes in infected horses. A major sequela that can occur after an EHV-1 infection is a neurological disease termed equine herpesvirus myeloencephalopathy (EHM). Clinical manifestations of EHM include fever, ataxia, incontinence, and partial to full paralysis, which may ultimately lead to the euthanization of the infected horse. To develop an effective treatment strategy for EHM, it is critical that the specific virus-host interactions that lead to EHM be investigated so that safe and effective therapeutic interventions can be developed and delivered. In this study, we examined the ability of four non-steroidal anti-inflammatory drugs (NSAIDs), a steroidal anti-inflammatory drug (dexamethasone), a Rho-kinase (ROCK) inhibitor, and a JAK/STAT inhibitor (AG490) to reduce EHV-1 virus yields and cell-to-cell spread. We show that the NSAID, flunixin meglumine (FM), and the JAK/STAT inhibitor, AG490, significantly reduced virus yields in endothelial and epithelial cell lines, and this inhibition was similar for two neurologic and two non-neurologic EHV-1 strains. In addition to reducing virus yields, AG490 and FM also significantly reduced the ability of EHV-1 to spread laterally from cell to cell.
Copyright © 2023 Black and Frampton.
Get Full Text
Publication Date: 2023-05-19 PubMed ID: 37275614PubMed Central: PMC10235532DOI: 10.3389/fvets.2023.1165917Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This study investigates the use of certain anti-inflammatory compounds to reduce the replication and spread of equine herpesvirus type 1 (EHV-1), a virus that can lead to severe neurological illnesses in horses.

Objective of the research

  • The main goal of the study was to evaluate the impact of different anti-inflammatory compounds on the replication and cell-to-cell spread of EHV-1. This was done with the aim of identifying potential therapeutic interventions for equine herpesvirus myeloencephalopathy (EHM), a serious neurological condition that can result from EHV-1 infection and could force euthanization of the infected horse.

Research Methods and Compounds Tested

  • The study specifically looked at four non-steroidal anti-inflammatory drugs (NSAIDs), a steroidal anti-inflammatory drug (dexamethasone), a Rho-kinase inhibitor, and a JAK/STAT inhibitor (AG490), and their effect on EHV-1 virus yields and spread.

Results of the study

  • The results of the study showed that flunixin meglumine (FM) – an NSAID, and AG490 – a JAK/STAT inhibitor, significantly reduced virus yields in endothelial and epithelial cell lines. This level of inhibition was similar for both neurologic and non-neurologic EHV-1 strains, indicating that these compounds could be effective against different forms of the virus.
  • Notably, AG490 and FM also notably reduced the ability of the EHV-1 to spread laterally from cell-to-cell. This is highly significant as it could potentially prevent the spread of the virus within the host, thus curtailing the progress and severity of the infection.

Implication of the Research

  • The findings of this research could pave the way for the development of a new therapeutic approach for EHM, by controlling and reducing the spread of EHV-1 using the compounds tested. This could potentially save many horses from being euthanized due to severe neurological illness resulting from EHV-1 infection.

Cite This Article

APA
Black JB, Frampton AR. (2023). Anti-inflammatory compounds reduce equine herpesvirus type 1 replication and cell-to-cell spread. Front Vet Sci, 10, 1165917. https://doi.org/10.3389/fvets.2023.1165917

Publication

Frontiers in veterinary science
ISSN: 2297-1769
NlmUniqueID: 101666658
Country: Switzerland
Language: English
Volume: 10
Pages: 1165917

Researcher Affiliations

Black, Jeanette B
  • Department of Biology and Marine Biology, University of North Carolina Wilmington, Wilmington, NC, United States.
Frampton, Arthur R
  • Department of Biology and Marine Biology, University of North Carolina Wilmington, Wilmington, NC, United States.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

This article includes 42 references
  1. Allen GP, Bryans JT. Molecular epizootiology, pathogenesis, and prophylaxis of equine herpesvirus-1 infections.. Prog Vet Microbiol Immunol (1986) 2:78–144.
    pubmed: 2856183
  2. O'Callaghan DJ, Gentry GA, Randall CC. The equine herpesviruses.. In:Roizman B, editors. The Herpesviruses, Comprehensive Virology, Vol 2. New York, NY: Plenum Press; (1983). p. 215–238.
  3. Ostlund EN. The equine herpesviruses.. Vet Clin N Am Equine Pract (1993) 9:283–94.
    doi: 10.1016/S0749-0739(17)30396-6pubmed: 8395324google scholar: lookup
  4. Goodman LB, Loregian A, Perkins GA, Nugent J, Buckles EL, Mercorelli B. A point mutation in a herpesvirus polymerase determines neuropathogenicity.. PLoS Pathog (2007) 3:e160.
    doi: 10.1371/journal.ppat.0030160pmc: PMC2065875pubmed: 17997600google scholar: lookup
  5. Perkins GA, Goodman LB, Tsujimura K, Van de Walle GR, Kim SG, Dubovi EJ. Investigation of the prevalence of neurologic equine herpes virus type 1 (EHV-1) in a 23-year retrospective analysis (1984-2007).. Vet Microbiol (2009) 139:375–8.
    doi: 10.1016/j.vetmic.2009.06.033pubmed: 19615831google scholar: lookup
  6. Nugent J, Birch-Machin I, Smith KC, Mumford JA, Swann Z, Newton JR. Analysis of equid herpesvirus 1 strain variation reveals a point mutation of the DNA polymerase strongly associated with neuropathogenic versus nonneuropathogenic disease outbreaks.. J Virol (2006) 80:4047–60.
    doi: 10.1128/JVI.80.8.4047-4060.2006pmc: PMC1440451pubmed: 16571821google scholar: lookup
  7. Smith KL, Allen GP, Branscum AJ, Frank Cook R, Vickers ML, Timoney PJ. The increased prevalence of neuropathogenic strains of EHV-1 in equine abortions.. Vet Microbiol (2010) 141:5–11.
    doi: 10.1016/j.vetmic.2009.07.030pubmed: 19733451google scholar: lookup
  8. Allen GP. Development of a real-time polymerase chain reaction assay for rapid diagnosis of neuropathogenic strains of equine herpesvirus-1.. J Vet Diagn Invest (2007) 19:69–72.
    doi: 10.1177/104063870701900110pubmed: 17459834google scholar: lookup
  9. Van de Walle GR, Goupil R, Wishon C, Damiani A, Perkins GA, Osterrieder N. single-nucleotide polymorphism in a herpesvirus DNA polymerase is sufficient to cause lethal neurological disease.. J Infect Dis (2009) 200:20–5.
    doi: 10.1086/599316pubmed: 19456260google scholar: lookup
  10. Allen GP. Risk factors for development of neurologic disease after experimental exposure to equine herpesvirus-1 in horses.. Am J Vet Res (2008) 69:1595–600.
    doi: 10.2460/ajvr.69.12.1595pubmed: 19046006google scholar: lookup
  11. Allen GP, Breathnach CC. Quantification by real-time PCR of the magnitude and duration of leucocyte-associated viraemia in horses infected with neuropathogenic vs. non-neuropathogenic strains of EHV-1.. Equine Vet J (2006) 38:252–7.
    doi: 10.2746/042516406776866453pubmed: 16706281google scholar: lookup
  12. Pusterla N, Hussey GS. Equine herpesvirus 1 myeloencephalopathy.. Vet Clin N Am Equine Pract (2014) 30:489–506.
    doi: 10.1016/j.cveq.2014.08.006pubmed: 25300635google scholar: lookup
  13. Edington N, Bridges CG, Patel JR. Endothelial cell infection and thrombosis in paralysis caused by equid herpesvirus-1: equine stroke.. Arch Virol (1986) 90:111–24.
    doi: 10.1007/BF01314149pubmed: 3015074google scholar: lookup
  14. Wagner B, Wimer C, Freer H, Osterrieder N, Erb HN. Infection of peripheral blood mononuclear cells with neuropathogenic equine herpesvirus type-1 strain Ab4 reveals intact interferon-alpha induction and induces suppression of anti-inflammatory interleukin-10 responses in comparison to other viral strains.. Vet Immunol Immunopathol (2011) 143:116–24.
    doi: 10.1016/j.vetimm.2011.06.032pubmed: 21764140google scholar: lookup
  15. Kydd JH, Slater J, Osterrieder N, Lunn DP, Antczak DF, Azab W. Third International Havemeyer Workshop on Equine Herpesvirus type 1.. Equine Vet J (2012) 44:513–7.
    doi: 10.1111/j.2042-3306.2012.00604.xpubmed: 22888774google scholar: lookup
  16. Johnstone S, Barsova J, Campos I, Frampton AR. Equine herpesvirus type 1 modulates inflammatory host immune response genes in equine endothelial cells.. Vet Microbiol (2016) 192:52–9.
    doi: 10.1016/j.vetmic.2016.06.012pubmed: 27527764google scholar: lookup
  17. Ray N, Bisher ME, Enquist LW. Cyclooxygenase-1 and−2 are required for production of infectious pseudorabies virus.. J Virol (2004) 78:12964–74.
    doi: 10.1128/JVI.78.23.12964-12974.2004pmc: PMC525029pubmed: 15542648google scholar: lookup
  18. Zhao X, Tong W, Song X, Jia R, Li L, Zou Y. Antiviral effect of resveratrol in piglets infected with virulent pseudorabies virus.. Viruses (2018) 10.
    doi: 10.3390/v10090457pmc: PMC6164078pubmed: 30150559google scholar: lookup
  19. Boodhoo N, Kamble N, Kaufer BB, Behboudi S. Replication of Marek's disease virus is dependent on synthesis of de novo fatty acid and prostaglandin E2.. J Virol (2019) 93.
    doi: 10.1128/JVI.00352-19pmc: PMC6580946pubmed: 30971474google scholar: lookup
  20. Schroer J, Shenk T. Inhibition of cyclooxygenase activity blocks cell-to-cell spread of human cytomegalovirus.. Proc Natl Acad Sci USA (2008) 105:19468–73.
    doi: 10.1073/pnas.0810740105pmc: PMC2614784pubmed: 19033472google scholar: lookup
  21. Zhu H, Cong JP, Yu D, Bresnahan WA, Shenk TE. Inhibition of cyclooxygenase 2 blocks human cytomegalovirus replication.. Proc Natl Acad Sci USA (2002) 99:3932–7.
    doi: 10.1073/pnas.052713799pmc: PMC122626pubmed: 11867761google scholar: lookup
  22. Haile WB, Gavegnano C, Tao S, Jiang Y, Schinazi RF, Tyor WR. The Janus kinase inhibitor ruxolitinib reduces HIV replication in human macrophages and ameliorates HIV encephalitis in a murine model.. Neurobiol Dis (2016) 92:137–43.
    doi: 10.1016/j.nbd.2016.02.007pmc: PMC4907871pubmed: 26851503google scholar: lookup
  23. Reece MD, Song C, Hancock SC, Pereira Ribeiro S, Kulpa DA, Gavegnano C. Repurposing BCL-2 and Jak 1/2 inhibitors: cure and treatment of HIV-1 and other viral infections.. Front Immunol (2022) 13:1033672.
    doi: 10.3389/fimmu.2022.1033672pmc: PMC9782439pubmed: 36569952google scholar: lookup
  24. Gavegnano C, Haile WB, Hurwitz S, Tao S, Jiang Y, Schinazi RF. Baricitinib reverses HIV-associated neurocognitive disorders in a SCID mouse model and reservoir seeding in vitro.. J Neuroinflammation (2019) 16:182.
    doi: 10.1186/s12974-019-1565-6pmc: PMC6764124pubmed: 31561750google scholar: lookup
  25. Gavegnano C, Bassit LC, Cox BD, Hsiao HM, Johnson EL, Suthar M. Jak inhibitors modulate production of replication-competent zika virus in human hofbauer, trophoblasts, and neuroblastoma cells.. Pathog Immun (2017) 2:199–218.
    doi: 10.20411/pai.v2i2.190pmc: PMC5538373pubmed: 28776046google scholar: lookup
  26. Stebbing J, Sanchez Nievas G, Falcone M, Youhanna S, Richardson P. JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality.. Sci Adv (2021) 7.
    doi: 10.1126/sciadv.abe4724pmc: PMC7775747pubmed: 33187978google scholar: lookup
  27. Poelaert KCK, Van Cleemput J, Laval K, Favoreel HW, Soboll Hussey G, Maes RK. Abortigenic but not neurotropic equine herpes virus 1 modulates the interferon antiviral defense.. Front Cell Infect Microbiol (2018) 8:312.
    doi: 10.3389/fcimb.2018.00312pmc: PMC6144955pubmed: 30258819google scholar: lookup
  28. Neubauer A, Osterrieder N. Equine herpesvirus type 1 (EHV-1) glycoprotein K is required for efficient cell-to-cell spread and virus egress.. Virology (2004) 329:18–32.
    doi: 10.1016/j.virol.2004.07.034pubmed: 15476871google scholar: lookup
  29. Frampton AR Jr, Smith PM, Zhang Y, Matsumura T, Osterrieder N, O'Callaghan DJ. Contribution of gene products encoded within the unique short segment of equine herpesvirus 1 to virulence in a murine model.. Virus Res (2002) 90:287–301.
    doi: 10.1016/S0168-1702(02)00245-9pubmed: 12457983google scholar: lookup
  30. Ziegler A, Fogle C, Blikslager A. Update on the use of cyclooxygenase-2-selective nonsteroidal anti-inflammatory drugs in horses.. J Am Vet Med Assoc (2017) 250:1271–4.
    doi: 10.2460/javma.250.11.1271pmc: PMC5588883pubmed: 28509650google scholar: lookup
  31. Knych HK. Nonsteroidal anti-inflammatory drug use in horses.. Vet Clin N Am Equine Pract (2017) 33:1–15.
    doi: 10.1016/j.cveq.2016.11.001pubmed: 28190614google scholar: lookup
  32. Castagnetti C, Mariella J. Anti-inflammatory drugs in equine neonatal medicine. Part II: corticosteroids.. J Eq Vet Sci (2015) 35:547–54.
    doi: 10.1016/j.jevs.2015.02.012google scholar: lookup
  33. Reed SM, Furr M, Howe DK, Johnson AL, MacKay RJ, Morrow JK. Equine protozoal myeloencephalitis: an updated consensus statement with a focus on parasite biology, diagnosis, treatment, and prevention.. J Vet Int Med (2016) 30:491–502.
    doi: 10.1111/jvim.13834pmc: PMC4913613pubmed: 26857902google scholar: lookup
  34. Goehring L, Brandes KM, Wittenburg L. Anti-inflammatory drugs decrease the rate of endothelial cell infection with EHV-1 in vitro.. In: Proceedings of 2012 Veterinary Symposium. New Orleans, LA: American College of Veterinary Internal Medicine; (2012)..
  35. Oladunni FS, Sarkar S, Reedy S, Balasuriya UBR, Horohov DW, Chambers TM. Equid herpesvirus 1 targets the sensitization and induction steps to inhibit the type I interferon response in equine endothelial cells.. J Virol (2019) 93.
    doi: 10.1128/JVI.01342-19pmc: PMC6854505pubmed: 31511388google scholar: lookup
  36. Sarkar S, Balasuriya UB, Horohov DW, Chambers TM. Equine herpesvirus-1 infection disrupts interferon regulatory factor-3 (IRF-3) signaling pathways in equine endothelial cells.. Vet Immunol Immunopathol (2016) 173:1–9.
    doi: 10.1016/j.vetimm.2016.03.009pubmed: 27090619google scholar: lookup
  37. Frampton AR Jr, Smith PM, Zhang Y, Grafton WD, Matsumura T, Osterrieder N. Meningoencephalitis in mice infected with an equine herpesvirus 1 strain KyA recombinant expressing glycoprotein I and glycoprotein E.. Virus Genes (2004) 29:9–17.
    doi: 10.1023/B:VIRU.0000032785.19420.14pubmed: 15215680google scholar: lookup
  38. Maxwell LK, Bentz BG, Gilliam LL, Ritchey JW, Pusterla N, Eberle R. Efficacy of the early administration of valacyclovir hydrochloride for the treatment of neuropathogenic equine herpesvirus type-1 infection in horses.. Am J Vet Res (2017) 78:1126–39.
    doi: 10.2460/ajvr.78.10.1126pmc: PMC6440545pubmed: 28945127google scholar: lookup
  39. Frampton AR Jr, Smith PM, Zhang Y, Matsumura T, Osterrieder N, O'Callaghan DJ. Equine herpesvirus type 1 (EHV-1) utilizes microtubules, dynein, and ROCK1 to productively infect cells.. Vet Microbiol (2010) 141:12–21.
    doi: 10.1016/j.vetmic.2009.07.035pmc: PMC2819619pubmed: 19713056google scholar: lookup
  40. Frampton AR Jr, Stolz DB, Uchida H, Goins WF, Cohen JB, Glorioso JC. Equine herpesvirus 1 enters cells by two different pathways, and infection requires the activation of the cellular kinase ROCK1.. J Virol (2007) 81:10879–89.
    doi: 10.1128/JVI.00504-07pmc: PMC2045510pubmed: 17670830google scholar: lookup
  41. Poelaert KCK, Van Cleemput J, Laval K, Xie J, Favoreel HW, Nauwynck HJ. Equine herpesvirus 1 infection orchestrates the expression of chemokines in equine respiratory epithelial cells.. J Gen Virol (2019).
    doi: 10.1099/jgv.0.001317pubmed: 31490114google scholar: lookup
  42. Thieulent CJ, Sutton G, Toquet MP, Fremaux S, Hue E, Fortier C. Oral administration of valganciclovir reduces clinical signs, virus shedding and cell-associated viremia in ponies experimentally infected with the equid herpesvirus-1 C(2254) variant.. Pathogens (2022) 11.
    pmc: PMC9148010pubmed: 35631060
Subscribe to our newsletter
Join 99,383 horse owners like you who receive our email updates on horse health and nutrition.